Article Text

This article has a correction. Please see:

Download PDFPDF
Retinal venous occlusion associated with depot medroxyprogesterone acetate
  1. Byron F Deen,
  2. R Keith Shuler, Jr,
  3. Sharon Fekrat
  1. Albert Eye Research Institute of the Duke University Eye Center, Erwin Rd, Durham, NC 27710, USA
  1. Sharon Fekrat, Duke Eye Center, DUMC Box 3802, Erwin Rd, Durham, NC 27710, USA; fekra001{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Although it is well-established that oestrogen-containing contraception has prothrombotic potential in women over 35 years of age, particularly in women who smoke, low dose progesterone-containing contraception, both oral and parenteral, has not been conclusively linked to prothrombotic events. We evaluated two patients who developed retinal vein occlusion after administration of depot medroxyprogesterone acetate (DMPA, Depo-ProveraTM, Pharmacia & Upjohn, Kalamazoo, Michigan, USA) for contraception.

Case reports

A 44-year-old, hypertensive, woman who smoked, presented with decreased visual acuity to the level of 6/200 in the left eye. A non-perfused hemiretinal vein occlusion was present. Ten weeks earlier, she had received a DMPA injection.

Nine months later, her right eye developed a non-perfused central retinal vein occlusion with decreased visual acuity …

View Full Text


  • Competing interests: None.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd.BMA House, Tavistock Square, London, WC1H 9JR